CordenPharma Expands Service Offerings
PTSM: Pharmaceutical Technology Sourcing and Management
The company expanded its services to include oligonucleotide API development and manufacturing and received approval for its Caponago manufacturing facility.
On July 1, 2016, CordenPharma announced that it has expanded its services to include oligonucleotide API development and manufacturing. The investment was initiated by CordenPharma Colorado and is expected to be complete before the end of 2016, the company said in a press announcement. Corden’s portfolio for API and drug products includes peptides, lipids, and carbohydrates for API manufacturing and development. In late June, the Italian Medicines Agency approved Corden’s sterile injectable facility in Caponago, Italy. The manufacturing facility, which was recently completed, will support customer development and commercial programs by providing service in aseptic filling of liquid and lyophilized vials, and pre-filled syringes. This adds to the facility’s existing terminal sterilization capabilities.
Source: Corden Pharma
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
A Novel, Enhanced, and Sustainable Approach to Audit Trail Review
July 4th 2025Eli Lilly and Company developed an innovative and sustainable approach to audit trail review (ATR) aimed at reducing the ATR burden while adhering to regulatory expectations and data integrity (DI) principles. The process has transformed employees' understanding of ATR and complemented the DI by design approach, leading to better system designs that meet expected controls and reduce non-value-added data reviews.
